以下文章来源于侃见财经 ，作者侃见财经 看见不一样的财经！ "医美面膜第一股"业绩遭遇暴雷。 8月21日晚间，国货美妆企业——敷尔佳发布了2025年半年报，其中显示，敷尔佳实现营收8.63亿元，同比下滑8.15%；归母净利润为2.3亿元，同比大幅 下跌32.54%；归母扣非净利润为1.66亿元，同比大幅下滑48.66%，接近腰斩。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入(元) | 863, 112, 643. 06 | 939, 742, 187. 97 | -8. 15% | | 归属于上市公司股东的净利润(元) | 229, 656, 927. 58 | 340, 413, 344. 14 | -32. 54% | | 归属于上市公司股东的扣除非经常性损益 的净利润(元) | 166. 174. 897. 97 | 323, 694, 307. 05 | -48.66% | | 经营活动产生的现金流量净额(元) | 161, 632, 951. 75 | 356, 740, 821. 88 | -54. 69% | ...

Group 1 - Jiangning District has completed 36 projects and introduced new projects with a total investment exceeding 56 billion yuan in the first half of the year [1][2] - The Tianyin Health Innovation Park has been fully constructed, attracting nearly 10 companies in the biopharmaceutical sector, with a total building area of 395,000 square meters [1] - The high-end cosmetics production base and Huakang Zhenyan headquarters project, with a total investment of 1 billion yuan, will produce 25 million sets of cosmetics annually upon completion [2] Group 2 - Jiangning High-tech Zone successfully introduced 33 quality projects with a total investment of 10 billion yuan in the first half of the year, maintaining a leading position among high-tech zones in the city [2][3] - The Binjiang Economic Development Zone has signed 24 projects with investments over 1 billion yuan, totaling 4.02 billion yuan, and all major projects have resumed construction [3] - Jiangning District is focusing on a detailed monthly schedule to accelerate the development of major enterprises and improve project approval efficiency by 38% [4]

Core Viewpoint - Lin Qingxuan Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on the anti-wrinkle and firming skincare market with a strong emphasis on high-end skincare solutions based on natural camellia ingredients [1][2]. Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue grew from 691 million RMB to 1.21 billion RMB, while the net profit attributable to the parent company improved from a loss of 5.87 million RMB to a profit of 187 million RMB [7][9]. - The gross profit margin increased from 78% to 82.5% during the same period [8]. Sales and Distribution - Sales and distribution expenses reached 688 million RMB in 2024, exceeding 50% of the total revenue [1][9]. - The revenue from offline channels decreased from 54.7% in 2022 to 40.8% in 2024, while online channel revenue increased from 45.2% to 59.1% [4][6]. Product Portfolio - As of December 31, 2024, Lin Qingxuan offered 188 SKUs, with significant revenue contributions from essence oils, creams, lotions, and masks, each accounting for over 10% of total revenue [3][4]. Market Position - In 2024, Lin Qingxuan ranked first among all high-end domestic skincare brands in China by retail sales and was the only domestic brand among the top 15 high-end skincare brands, which included both domestic and international brands [2][3]. Use of Proceeds - The funds raised from the listing will be used for brand value enhancement, deepening the multi-channel sales network, and strengthening production and supply chain capabilities [10].

Group 1: Company Updates - Zhongxi Culture (INHI) has completed overseas listing filing, planning to issue 1.25 million shares at a price range of $4 to $5 per share, aiming to raise between $5 million and $6.25 million [1] - Meihua Chuangfu (MGRT) plans to issue 3.75 million shares at a price range of $4 to $5 per share, with a fundraising target of $15 million to $18.75 million [2] - Pitanium (PTNM) intends to issue 1.75 million shares at a price range of $4 to $5 per share, seeking to raise between $7 million and $8.75 million [4] Group 2: Financial Performance - Zhongxi Culture reported revenue of $20.63 million for 2024, a slight decrease from $21.03 million in the previous year, with net profits of $4.19 million compared to $3.28 million [2] - Meihua Chuangfu generated revenue of $3.33 million for the fiscal year ending September 30, with a net profit of $0.4 million [4] - Pitanium achieved revenue of $9.59 million for the fiscal year ending September 30, with a net profit of $1.14 million [5]